HIV/AIDS Joint Action HA-REACT

Transcription

1 HIV/AIDS Joint Action HA-REACT Matthias Schuppe Policy Officer Health Threats Unit DG Health and Food Safety European Commission

2 Policy Framework on HIV/AIDS in EU and neighbouring countries Commission Communication on Combating HIV/AIDS in the European Union and neighbouring countries COM(2009)569, Annexed to it Action Plan Action Plan on HIV/AIDS in the EU and neighbouring countries: , SWD(2014) 106 final (published on 14 th March 2014)

3 Commission policy priorities on HIV/AIDS Main objectives of the policy framework: 1. To reduce HIV infections 2. To improve access to prevention, treatment and care 3. To improve the quality of life of people living with HIV/AIDS

4 The focus of the Commission Communication and action plan Politics & policies (political leadership) Prevention (+treatment) Priority groups (MSM, IDUs, migrants) Broad involvement of Civil Society and other stakeholders Priority regions (East European EUMS, and neighbouring countries to the East) Knowledge base and dissemination

5 Action Plan 2014: focus on PWID 4. Priority groups Implementation of risk and harm reduction measures to IDUs and their partners for prevention and treatment of HIV, co-infections and drug dependency in the community and in prisons Increased focus on additional risk groups such as prisoners and sex workers.

6 Health Programme HIV/AIDS and co-infections as priority 1.3. Support effective response to communicable diseases such as HIV/AIDS, tuberculosis and hepatitis by identifying, disseminating and promoting the up-take of good practices for cost effective prevention, diagnosis, treatment and care.

7 HA-REACT - Joint Action on HIV and coinfection prevention and harm reduction EC Budget (co-financing): Euro 3 Million; Duration: 36 months;

8 HA-REACT - Joint Action on HIV and coinfection prevention and harm reduction To stop (eradicate) transmission of blood-borne and poverty related infectious diseases among people who inject drugs (PWID) in the EU By implementing country-tailored preventive interventions, using well tried evidence based harm reduction approaches Creating sustained, improved capacity of all EU countries to respond to infection risks and vulnerabilities among (PWID) Specific focus on Latvia, Lithuania and Hungary, but engaging all partner countries

9 Zero new HIV, reduced HCV and TB among PWID in the EU by 2020 Improved prevention and treatment of blood-borne infections and TB in priority regions and priority groups in the European Union Improved capacity to respond to HIV and co-infection risks and provide harm reduction with specific focus on people who inject drugs (PWID) in the EU 0. Managem ent of the Joint action 1. Improved early 1. Improved diagnosis early of HIV, diagnosis viral hepatitis of HIV, viral and TB hepatitis, as well and as TB improve among d PWID linkage in to Latvia care and for Hungary PWID (WP4) 2. Harm reduction 2. Harm scaled reduction up in EU scaled based up on in Latvian and Lithuanian (WP5) cases (WP5) Increased Harm harm reduction reduction and continuity and improved of care continuity for prisoners of care who for use PWID drugs in prison enhanced settings (WP6) 4. Improved provision of integrated HIV, HCV, TB TB treatment and drug and treatment harm reduction for PWID for PWID (WP7) (WP7) 5. National programmes updated to overcome barriers to respond to HIV, HCV and TBrelated needs of PWID in the EU (WP8) Outi Karvonen 9

10 Associated and affiliated partners: 24+2 from 19 countries Belgium (BE) Modus vivendi asbl Croatia (HR) Croatian institute of Public Health (HZJZ) Life Quality Improvement Organisation FLIGHT (LET) Czech Republic (CZ) National monitoring center for drugs and additions (NMS) Denmark (DK) Centre for Health and Infectious disease Research, Rigshospitalet University of Copenhafen (CHIP) Estonia (EE) National Institute for Health Development (NIHD) Finland (FI) National Institute for Health and Welfare (THL) Germany (DE) Zentrum fur interdisziplinare Suchtforschung der Universitat Hamburg (ZIS) Institut fur Suchtforschung (ISFF) Deutsche AIDS-Hilfe (DAH) Affiliated: Germany (DE) AIDS Action Europe (AAE) Greece (EL) Hellenic Center For Disease Control Ανd Preventlon (HCDCP) Hungary (HU) OEK (National Centre for Epidemiology) (Országos Epidemiológiai Központ) Office of the Chief Medical Officer (OCMO), (OTH, Országos Tisztifőorvosi Hivatal) Iceland (IS) Landspitali University Hospital Italy (IT) Istituto Nazionale Malattie Infettive (INMI) Latvia (LV) Center For Disease Prevention and control of Latvia Lithuania (LT) Center For Communicable Diseases And Aids (ULAC) Vilnius Center For Addictive Disorder (VPLC) Luxembourg (LU) Directorate of Health (Ministry of Health) Division of Health Inspection Malta (MT) Ministry for Energy and Health (MEH) Poland (PL) National Centre AIDS Agenda of the Ministry of Health (NAC Poland) Portugal (PT) Directorate-General of Health (DGS) Slovenia (SI) Association SKUC Miran Solinc Spain (ES) Instituto de Salud Carlos III Affiliated:Centro de Investigacion Biomedica end Red (CIBER) Mika Salminen/Outi Karvonen 10

11 Collaborating partners: 12 with an additional 4 countries and 2 EU agencies Norway (NO) Norwegian Institute of Public Health, Oslo Sweden (SE) Public Health Agency of Sweden, Stockholm United Kingdom (UK) Department of Health, London Cyprus (CY) Medical and Public Health Services of the Ministry of Health of the Republic of Cyprus Czech Republic (CZ): The Czech AIDS help Society (CSAP) The national institute of Public Health (SZU) Ministry of Health (MZ CR) Spain (ES) Coordinadora Estatal de VIH-SIDA (CESIDA) Belgium (BE) Free Clinic Lithuania (LT) Vilnius University EU Agencies European Centre for Disease Prevention and Control (ECDC) European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Mika Salminen/Outi Karvonen 11

12 Thank you for your attention! For more information contact Matthias Schuppe Policy Officer Health Threats Unit DG Health and Food Safety European Commission